«Previous Article|Table of Contents|Next Article»

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:

2023 15

Page:

2872-2878

Research Field:

Publishing date:

Info

Title:

Peripheral blood cytokines predict the efficacy and prognosis of anti-PD-1 therapy for advanced gastric cancer

Author(s):

WANG Xinyan¹; DAI Huwei²; LIU Xiaoling³

1.The First Clinical Medical College of Shanxi Medical University,Shanxi Taiyuan 030001,China£»2.The Second Clinical Medical College of Shanxi Medical University,Shanxi Taiyuan 030001,China;3.Department of Special Medical,Shanxi Province Cancer Hospital,Shanxi Hospital Affiliated to Cancer Hospital,Chinese Academy of Medical Sciences,Cancer Hospital Affiliated to Shanxi Medical University,Shanxi Taiyuan 030013,China.

Keywords:

advanced gastric cancer; biomarkers; cytokines; immunotherapy

PACS:

R735.2

DOI:

10.3969/j.issn.1672-4992.2023.15.020

Abstract:

Objective£ºTo investigate the relationship between peripheral blood cytokines(interleukin-2,interleukin-4,interleukin-6,interleukin-10,interleukin-17A) and the efficacy and prognosis of immunotherapy in advanced gastric cancer patients.Methods£ºThe clinicopathological data of 88 patients with advanced gastric cancer admitted to Shanxi Province Cancer Hospital with immunotherapy and the detection data of interleukin-2,interleukin-4,interleukin-6,interleukin-10,interleukin-17A in peripheral blood before immunotherapy were collected from 01,2020 to 10,2021.Factors affecting cytokines in patients were analyzed by t-test.The differences in DCR and ORR between different groups were analyzed using chi-square test.Logistic regression was used to analyze the relationship between interleukin-6,interleukin-10 and treatment effect and to draw ROC curves.The Kaplan-Meier method was used to plot survival curves and the differences in survival curves were examined by Log-rank test.Cox risk proportional model was used to analyze the relationship between interleukin-2,interleukin-4,interleukin-6,interleukin-10,interleukin-17A and progression-free survival.Results£ºThe study showed that age,PD-L1 level,and MMR status could affect the peripheral blood cytokine levels in patients with advanced gastric cancer to some extent.In the prognostic analysis,IL-6 (HR=2.593,95%CI:1.470~4.572,P=0.001),IL-10 (HR=0.384,95%CI:0.197~0.747,P=0.005),MMR status (HR=0.103,95%CI:0.039~0.274,P£¼0.001),PD-L1 expression (HR=0.229,95%CI:0.106~0.497,P£¼0.001) were independent predictors of immunotherapy PFS in patients with advanced gastric cancer.Conclusion£ºPeripheral IL-6 levels and IL-10 levels predict PFS of immunotherapy in patients with advanced gastric cancer.In the future,peripheral blood cytokines may be used as biomarkers for clinical screening of patients benefiting from immunotherapy.

References:

£Û1£ÝSUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries£ÛJ£Ý.CA Cancer J Clin,2021,71(3):209-249.
£Û2£ÝDIEM S,SCHMID S,KRAPF M,et al.Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab£ÛJ£Ý.Lung Cancer,2017,111:176-181.
£Û3£ÝYAN Y,WANG X,LIU C,et al.Association of lymphocyte subsets with efficacy and prognosis of immune checkpoint inhibitor therapy in advanced non-small cell lung carcinoma:a retrospective study£ÛJ£Ý.BMC Pulm Med,2022,22(1):166.
£Û4£ÝHUYNH J,CHAND A,GOUGH D,et al.Therapeutically exploiting STAT3 activity in cancer-using tissue repair as a road map£ÛJ£Ý.Nat Rev Cancer,2019,19(2):82-96.
£Û5£ÝBRIUKHOVETSKA D,D¦ZRR J,ENDRES S,et al.Interleukins in cancer:from biology to therapy£ÛJ£Ý.Nat Rev Cancer,2021,21(8):481-499.
£Û6£ÝMAO XC,YANG CC,YANG YF,et al.Peripheral cytokine levels as novel predictors of survival in cancer patients treated with immune checkpoint inhibitors:A systematic review and meta-analysis£ÛJ£Ý.Front Immunol,2022,13:884592.
£Û7£ÝHIAM-GALVEZ KJ,ALLEN BM£¬SPITZER MH.Systemic immunity in cancer£ÛJ£Ý.Nat Rev Cancer,2021,21(6):345-359.
£Û8£ÝANESTAKIS D,PETANIDIS S,KALYVAS S,et al.Mechanisms and applications of interleukins in cancer immunotherapy£ÛJ£Ý.Int J Mol Sci,2015,16(1):1691-1710.
£Û9£ÝTANIGUCHI K£¬KARIN M.IL-6 and related cytokines as the critical lynchpins between inflammation and cancer£ÛJ£Ý.Semin Immunol,2014,26(1):54-74.
£Û10£ÝHAM IH,OH HJ,JIN H,et al.Targeting interleukin-6 as a strategy to overcome stroma-induced resistance to chemotherapy in gastric cancer£ÛJ£Ý.Mol Cancer,2019,18(1):68.
£Û11£ÝWANG Y,RAMACHANDRAN V,SUI D,et al.Evaluation of plasma IL-6 in patients with melanoma as a prognostic and checkpoint immunotherapy predictive biomarker£ÛJ£Ý.J Invest Dermatol,2022,142(7):2046-2049.
£Û12£ÝPEDERSEN JG,MADSEN AT,GAMMELGAARD KR,et al.Inflammatory cytokines and ctDNA are biomarkers for progression in advanced-stage melanoma patients receiving checkpoint inhibitors£ÛJ£Ý.Cancers (Basel),2020,12(6):1414.
£Û13£ÝDAMUZZO V,SOLITO S,PINTON L,et al.Clinical implication of tumor-associated and immunological parameters in melanoma patients treated with ipilimumab£ÛJ£Ý.Oncoimmunology,2016,5(12):e1249559.
£Û14£ÝARENDS R,GUO X,BAVEREL PG,et al.Association of circulating protein biomarkers with clinical outcomes of durvalumab in head and neck squamous cell carcinoma£ÛJ£Ý.Oncoimmunology,2021,10(1):1898104.
£Û15£ÝKEEGAN A,RICCIUTI B,GARDEN P,et al.Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC£ÛJ£Ý.J Immunother Cancer,2020,8(2):e000678.
£Û16£ÝDE KLERK LK,PATEL AK,DERKS S,et al.Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival£ÛJ£Ý.J Immunother Cancer,2021,9(9):e002472.
£Û17£ÝDELYON J£¬LEBBE C.IL-6 blockade in cancer patients treated with immune checkpoint blockade:A win-win strategy£ÛJ£Ý.Cancer Cell,2022,40(5):450-451.
£Û18£ÝCHEN H,ZHOU J,LUO J,et al.Serum multi-cytokines screening identifies TRAIL and IL-10 as probable new biomarkers for prostate health index diagnostic utility adjustment in grey zone aggressive prostate cancer detection:A single-center data in China£ÛJ£Ý.Front Immunol,2022,13:901176.
£Û19£ÝCHANG J,ZHANG W,LIN G,et al.Tumor response to irinotecan is associated with IL-10 expression level in metastatic colorectal cancer-results from mCRC biomarker study£ÛJ£Ý.Onco Targets Ther,2020,13:11819-11826.
£Û20£ÝZHANG H,LI R,CAO Y,et al.Poor clinical outcomes and immunoevasive contexture in intratumoral IL-10-producing macrophages enriched gastric cancer patients£ÛJ£Ý.Ann Surg,2022,275(4):e626-e635.
£Û21£ÝKOH J,KIM Y,LEE KY,et al.MDSC subtypes and CD39 expression on CD8(+) T cells predict the efficacy of anti-PD-1 immunotherapy in patients with advanced NSCLC£ÛJ£Ý.Eur J Immunol,2020,50(11):1810-1819.
£Û22£ÝLI S,CONG X,GAO H,et al.Tumor-associated neutrophils induce EMT by IL-17a to promote migration and invasion in gastric cancer cells£ÛJ£Ý.J Exp Clin Cancer Res,2019,38(1):6.
£Û23£ÝLIU C,LIU R,WANG B,et al.Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer£ÛJ£Ý.J Immunother Cancer,2021,9(1):e001895.
£Û24£ÝSONG X,TRAUB B,SHI J,et al.Possible roles of interleukin-4 and -13 and their receptors in gastric and colon cancer£ÛJ£Ý.Int J Mol Sci,2021,22(2):727.
£Û25£ÝC¦BRDENAS DM,S¦BNCHEZ AC,ROSAS DA,et al.Preliminary analysis of single-nucleotide polymorphisms in IL-10,IL-4,and IL-4R¦Á genes and profile of circulating cytokines in patients with gastric cancer£ÛJ£Ý.BMC Gastroenterol,2018,18(1):184.
£Û26£ÝHARDY-WERBIN M,ROCHA P,ARPI O,et al.Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer£ÛJ£Ý.Oncoimmunology,2019,8(6):e1593810.
£Û27£ÝDHUPKAR P,GORDON N.Interleukin-2:Old and new approaches to enhance immune-therapeutic efficacy£ÛJ£Ý.Adv Exp Med Biol,2017,995:33-51.
£Û28£ÝYANG J,CAO W,XING E.Levels and significance of tumor markers and cytokines in serum and peritoneal lavage fluid of patients with peritoneal metastasis of gastric cancer£ÛJ£Ý.Biomed Res Int,2022,2022:9528444.
£Û29£ÝHASHIMOTO M,ARAKI K,CARDENAS MA,et al.PD-1 combination therapy with IL-2 modifies CD8(+) T cell exhaustion program£ÛJ£Ý.Nature,2022,610(7930):173-181.

Memo

Memo:

Îâ½×ƽ»ù½ð(±àºÅ£º320.6750.2020-01-14)

Common functions

Last Update: 2023-06-30